Drug Search Results
More Filters [+]

Isavuconazole

Alternative Names: isavuconazole
Latest Update: 2024-06-25
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: CYP3A4 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral,Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Argentina | Australia | Austria | Belgium | Canada | Cyprus | Czech | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Greece | Hong Kong | Hungary | Iceland | India | Ireland | Israel | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Peru | Poland | Portugal | Romania | Russia | Serbia | Singapore | Slovakia | Slovenia | Spain | Sweden | Switzerland | United Arab Emirates | United Kingdom

Approved Indications: None

Known Adverse Events: None

Company: Astellas Pharma
Company Location: NEW YORK NY 10005
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Isavuconazole

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Lung Transplant|Invasive Fungal Infections

Phase 3: Invasive Pulmonary Aspergillosis|Candidemia|Aspergillosis|Invasive Fungal Infections|Coronavirus Infections|Severe Acute Respiratory Syndrome|Candidiasis, Invasive|Acute Myeloid Leukemia

Phase 2: Neutropenia|Preleukemia|Acute Myeloid Leukemia|Myelodysplastic Syndrome|Myeloproliferative Disorders|Invasive Pulmonary Aspergillosis|Pulmonary Aspergillosis|Aspergillosis

Phase 1: Healthy Volunteers|Kidney Diseases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ChiCTR2400086245

N/A

Not yet recruiting

Aspergillosis|Mucormycosis

2026-06-30

YJK-001

N/A

Not yet recruiting

Mucormycosis|Aspergillosis

2026-06-30

C3791001

P4

Recruiting

Invasive Fungal Infections

2025-06-27

IA-DUET

P3

Terminated

Aspergillosis

2024-05-01

Recent News Events